Hirofumi Amano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hirofumi Amano has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Yoshinari Takasaki
A Department of Internal Medicine and Rheumatology , Juntendo University School of Medicine , Tokyo , Japan
5 shared publicationsKen Yamaji
Juntendo University
4 shared publicationsNaoto Tamura
Department of Internal Medicine and Rheumatology, Faculty of Medicine, Juntendo University, Tokyo, Japan
3 shared publicationsKentaro Minowa
Department of Rheumatology and Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan
2 shared publicationsMichihiro Ogasawara
A Department of Internal Medicine and Rheumatology , Juntendo University School of Medicine , Tokyo , Japan
2 shared publications- Naoto Tamura
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo
2 shared publications
Latest Publications
- Open Access
- 7 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2)
Anti-PM/Scl Antibody-Positive Dermatomyositis With Rapidly Progressive Interstitial Lung Disease in a 19-Year-Old Male: Clinical Implications of a Presumptive Diagnosis Based on Line Immunoassay Positivity
Anti-PM/Scl antibodies are classically linked to systemic sclerosis-polymyositis overlap, but a dermatomyositis phenotype with interstitial lung disease has also been described. However, the clinical course and therapeutic approach for short-term progressive interstitial lung disease in anti-PM/Scl-positive dermatomyositis remain incompletely defined. A 19-year-old Japanese male developed cough and exertional dyspnea after several weeks of progressive myalgia and proximal muscle weakness. Marked creatine kinase elevation, a high-titer nucleolar-pattern antinuclear antibody, Gottron papules, and mechanic’s hands were noted, and dermatomyositis was diagnosed based on muscle magnetic resonance imaging and skin histopathology. High-resolution chest computed tomography showed bilateral, lower-lobe-predominant ground-glass opacities with infiltrative changes, consistent with a subacute-to-rapidly progressive course of interstitial lung disease. Anti-PM/Scl-75 and PM/Scl-100 antibodies were positive by a line immunoassay. As immunoprecipitation was unavailable, orthogonal testing on a different platform (wet protein array) also demonstrated strong positivity, increasing diagnostic confidence. After methylprednisolone pulse therapy, followed by high-dose glucocorticoids, interstitial lung disease findings persisted, prompting initiation and up-titration of mycophenolate mofetil. Imaging abnormalities and serum Krebs von den Lungen-6 improved over time after mycophenolate mofetil initiation, although the independent effect could not be determined because multiple interventions overlapped. Intravenous immunoglobulin was added for residual myositis activity, leading to improvement in muscle enzymes and discharge. This case highlights that anti-PM/Scl-positive dermatomyositis in young adults can present with short-term progressive interstitial lung disease and illustrates a pragmatic diagnostic and therapeutic strategy when immunoprecipitation is not feasible.
- 7 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2)
Open AccessAnti-PM/Scl Antibody-Positive Dermatomyositis With Rapidly Progressive Interstitial Lung Disease in a 19-Year-Old Male: Clinical Implications of a Presumptive Diagnosis Based on Line Immunoassay Positivity
Anti-PM/Scl antibodies are classically linked to systemic sclerosis-polymyositis overlap, but a dermatomyositis phenotype with interstitial lung disease has also been described. However, the clinical course and therapeutic approach for short-term progressive interstitial lung disease in anti-PM/Scl-positive dermatomyositis remain incompletely defined. A 19-year-old Japanese male developed cough and exertional dyspnea after several weeks of progressive myalgia and proximal muscle weakness. Marked creatine kinase elevation, a high-titer nucleolar-pattern antinuclear antibody, Gottron papules, and mechanic’s hands were noted, and dermatomyositis was diagnosed based on muscle magnetic resonance imaging and skin histopathology. High-resolution chest computed tomography showed bilateral, lower-lobe-predominant ground-glass opacities with infiltrative changes, consistent with a subacute-to-rapidly progressive course of interstitial lung disease. Anti-PM/Scl-75 and PM/Scl-100 antibodies were positive by a line immunoassay. As immunoprecipitation was unavailable, orthogonal testing on a different platform (wet protein array) also demonstrated strong positivity, increasing diagnostic confidence. After methylprednisolone pulse therapy, followed by high-dose glucocorticoids, interstitial lung disease findings persisted, prompting initiation and up-titration of mycophenolate mofetil. Imaging abnormalities and serum Krebs von den Lungen-6 improved over time after mycophenolate mofetil initiation, although the independent effect could not be determined because multiple interventions overlapped. Intravenous immunoglobulin was added for residual myositis activity, leading to improvement in muscle enzymes and discharge. This case highlights that anti-PM/Scl-positive dermatomyositis in young adults can present with short-term progressive interstitial lung disease and illustrates a pragmatic diagnostic and therapeutic strategy when immunoprecipitation is not feasible.
- 24 November 2025
- Published by SAGE Publications in Lupus
- Vol. 35 (1) , 30-38
Efficacy of adding belimumab to hydroxychloroquine for patients with serologically active clinically quiescent in systemic lupus erythematosus: A retrospective study
Objectives: In systemic lupus erythematosus (SLE), a serologically active clinically quiescent (SACQ) state is defined as one in which high anti-DNA antibody levels or low complement levels persist, however, disease activity remains stable. Although treatment intensification is not recommended for the SACQ state under the Treat to Target strategy, SACQ has been reported to be a risk factor for flares. The present study aimed to evaluate the efficacy of adding belimumab (BLM) to hydroxychloroquine (HCQ), the standard treatment for SLE, for patients in the SACQ state. Methods: Patients treated with BLM were defined as the exposure group and those who did not were defined as the control group. Propensity score analysis with inverse probability of treatment weighting was used to analyze outcomes. The primary outcome was analyzed using the Kaplan–Meier method to determine time-to-event achievement to reduce prednisolone (PSL) dose to 7.5 mg/day or 5 mg/day. Secondary outcomes were as follows: (1) time to flares, analyzed using the Kaplan–Meier method, and (2) difference in median PSL dose at the last observation, analyzed using the Mann–Whitney U-test. Results: Of the 146 patients in the SACQ state who received HCQ, 27 were included in the exposure group and 107 in the control group. The primary outcome, time-to-event achievement to reduce PSL dose to 7.5 mg/day and 5 mg/day had an HR value of 1.21 (95% confidence interval (CI) 0.78–1.89, p = 0.396) and 1.19 (95% CI 0.74–1.89, p = 0.471) in the two groups, respectively, with no significant difference between the two groups. No significant differences were observed in other outcomes. Conclusions: Adding BLM to HCQ in patients in the SACQ state did not demonstrate effects in preventing flares or reducing glucocorticoids (GC) dose.
- 24 November 2025
- Published by SAGE Publications in Lupus
- Vol. 35 (1) , 30-38
Efficacy of adding belimumab to hydroxychloroquine for patients with serologically active clinically quiescent in systemic lupus erythematosus: A retrospective study
Objectives: In systemic lupus erythematosus (SLE), a serologically active clinically quiescent (SACQ) state is defined as one in which high anti-DNA antibody levels or low complement levels persist, however, disease activity remains stable. Although treatment intensification is not recommended for the SACQ state under the Treat to Target strategy, SACQ has been reported to be a risk factor for flares. The present study aimed to evaluate the efficacy of adding belimumab (BLM) to hydroxychloroquine (HCQ), the standard treatment for SLE, for patients in the SACQ state. Methods: Patients treated with BLM were defined as the exposure group and those who did not were defined as the control group. Propensity score analysis with inverse probability of treatment weighting was used to analyze outcomes. The primary outcome was analyzed using the Kaplan–Meier method to determine time-to-event achievement to reduce prednisolone (PSL) dose to 7.5 mg/day or 5 mg/day. Secondary outcomes were as follows: (1) time to flares, analyzed using the Kaplan–Meier method, and (2) difference in median PSL dose at the last observation, analyzed using the Mann–Whitney U-test. Results: Of the 146 patients in the SACQ state who received HCQ, 27 were included in the exposure group and 107 in the control group. The primary outcome, time-to-event achievement to reduce PSL dose to 7.5 mg/day and 5 mg/day had an HR value of 1.21 (95% confidence interval (CI) 0.78–1.89, p = 0.396) and 1.19 (95% CI 0.74–1.89, p = 0.471) in the two groups, respectively, with no significant difference between the two groups. No significant differences were observed in other outcomes. Conclusions: Adding BLM to HCQ in patients in the SACQ state did not demonstrate effects in preventing flares or reducing glucocorticoids (GC) dose.
- Open Access
- 18 March 2022
- Published by Elsevier in Regenerative Therapy
- Vol. 20, 18-25
Grafting of autologous concentrated bone marrow processed using a point-of-care device for patients with osteonecrosis of the femoral head: A phase 1 feasibility and safety study
- 18 March 2022
- Published by Elsevier in Regenerative Therapy
- Vol. 20, 18-25
Open AccessGrafting of autologous concentrated bone marrow processed using a point-of-care device for patients with osteonecrosis of the femoral head: A phase 1 feasibility and safety study
- 9 May 2021
- Published by SAGE Publications in Lupus
- Vol. 30 (9) , 1378-1384
Combining maintenance therapy with hydroxychloroquine increases LLDAS achievement rates in individuals with stable systemic lupus erythematosus
Background: Hydroxychloroquine (HCQ) has been positioned as an anchor drug for systemic lupus erythematosus (SLE). There is evidence supporting the benefits of HCQ; however, the effect of additional HCQ in maintenance therapy remains unclear. Methods: Thirty patients with SLE who visited Juntendo University Hospital were receiving maintenance therapy before HCQ treatment and were able to complete more than 104 weeks of HCQ treatment were analyzed. Anti-DNA antibody titers, IgG and CH50 levels, the maintenance dose of corticosteroids, the SLE disease activity index (SLEDAI), and the achievement of the Lupus Low Disease Activity State (LLDAS) were evaluated at baseline and at 12, 24, 52, and 104 weeks after HCQ initiation. Results: We observed improvements in the anti-DNA antibody titers, IgG and CH50 levels, maintenance dose of corticosteroids, and SLEDAI at week 104 relative to baseline. Moreover, the LLDAS achievement rate increased over time from 10% at baseline to 43% and 80% at week 52 and week 104, respectively. Conclusion: Two years of continuous HCQ treatment led to improvements in SLE disease activity and corticosteroid dose and an increase in LLDAS achievement, thereby demonstrating the significance of the maintenance dose of HCQ for the management of SLE.
- 9 May 2021
- Published by SAGE Publications in Lupus
- Vol. 30 (9) , 1378-1384
Combining maintenance therapy with hydroxychloroquine increases LLDAS achievement rates in individuals with stable systemic lupus erythematosus
Background: Hydroxychloroquine (HCQ) has been positioned as an anchor drug for systemic lupus erythematosus (SLE). There is evidence supporting the benefits of HCQ; however, the effect of additional HCQ in maintenance therapy remains unclear. Methods: Thirty patients with SLE who visited Juntendo University Hospital were receiving maintenance therapy before HCQ treatment and were able to complete more than 104 weeks of HCQ treatment were analyzed. Anti-DNA antibody titers, IgG and CH50 levels, the maintenance dose of corticosteroids, the SLE disease activity index (SLEDAI), and the achievement of the Lupus Low Disease Activity State (LLDAS) were evaluated at baseline and at 12, 24, 52, and 104 weeks after HCQ initiation. Results: We observed improvements in the anti-DNA antibody titers, IgG and CH50 levels, maintenance dose of corticosteroids, and SLEDAI at week 104 relative to baseline. Moreover, the LLDAS achievement rate increased over time from 10% at baseline to 43% and 80% at week 52 and week 104, respectively. Conclusion: Two years of continuous HCQ treatment led to improvements in SLE disease activity and corticosteroid dose and an increase in LLDAS achievement, thereby demonstrating the significance of the maintenance dose of HCQ for the management of SLE.
- Open Access
- 8 February 2018
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 20 (1) , 1-11
Anti-CD11b antibody treatment suppresses the osteoclast generation, inflammatory cell infiltration, and autoantibody production in arthritis-prone FcγRIIB-deficient mice
Previously we established an arthritis-prone FcγRIIB-deficient mouse strain (designated KO1). Anti-mouse CD11b mAb (5C6) has been reported to inhibit the recruitment of peripheral CD11b+ myelomonocytic cells from the blood to the inflammatory site. These cells include neutrophils and monocytes, both of which play important roles in the development of arthritis. Here we treated KO1 mice with 5C6 mAb in order to study its effect on arthritis development. To evaluate the disease-preventive effect of 5C6, 4-month-old preclinical KO1 mice were divided into three groups: the first treated with 5C6 for 6 months, the second treated with normal rat IgG for 6 months, as a control, and the third left untreated. Arthritis severity and immunological abnormalities were compared among the groups, along with transcriptional levels of several important arthritis-related factors in ankle joints, spleen, and peripheral blood cells. The 5C6 treatment ameliorated arthritis in KO1 mice, showing decreases in inflammatory cell infiltration and osteoclast formation. Analysis of transcriptional levels in ankle joints revealed that compared with the two control groups, the 5C6-treated group showed downregulated expression of RANK, RANKL, MCP-1, RANTES, TNFα, and IL-6, and at the same time showed significantly up-regulated expression of the decoy receptor for RANKL, i.e. osteoprotegerin. In addition, the disease suppression was associated with the lower serum levels of autoantibodies, and the decreased frequencies of activated B cells and plasma cells. The expression levels of B cell activation/differentiation-related cytokines were suppressed in spleen and peripheral leukocytes of the 5C6-treated mice. Intriguingly, while untreated KO1 mice spontaneously developed marked monocytosis, the 5C6-treated mice showed the significantly down-regulated frequency of monocytes. The outcome of 5C6 treatment was complex, in which the 5C6-mediated disease-preventive effect is likely due on one hand to the decrease in the recruitment of inflammatory cells and osteoclast precursor monocytes from the periphery into the joints, and on the other hand to the suppression of B cell activation/maturation and of autoantibody production via the suppression of B cell stimulating cytokine production. The lower levels of these cytokines may be the secondary effect of the lower frequency of monocytes, since monocytes/macrophages are the major producers of these cytokines.
- 8 February 2018
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 20 (1) , 1-11
Open AccessAnti-CD11b antibody treatment suppresses the osteoclast generation, inflammatory cell infiltration, and autoantibody production in arthritis-prone FcγRIIB-deficient mice
Previously we established an arthritis-prone FcγRIIB-deficient mouse strain (designated KO1). Anti-mouse CD11b mAb (5C6) has been reported to inhibit the recruitment of peripheral CD11b+ myelomonocytic cells from the blood to the inflammatory site. These cells include neutrophils and monocytes, both of which play important roles in the development of arthritis. Here we treated KO1 mice with 5C6 mAb in order to study its effect on arthritis development. To evaluate the disease-preventive effect of 5C6, 4-month-old preclinical KO1 mice were divided into three groups: the first treated with 5C6 for 6 months, the second treated with normal rat IgG for 6 months, as a control, and the third left untreated. Arthritis severity and immunological abnormalities were compared among the groups, along with transcriptional levels of several important arthritis-related factors in ankle joints, spleen, and peripheral blood cells. The 5C6 treatment ameliorated arthritis in KO1 mice, showing decreases in inflammatory cell infiltration and osteoclast formation. Analysis of transcriptional levels in ankle joints revealed that compared with the two control groups, the 5C6-treated group showed downregulated expression of RANK, RANKL, MCP-1, RANTES, TNFα, and IL-6, and at the same time showed significantly up-regulated expression of the decoy receptor for RANKL, i.e. osteoprotegerin. In addition, the disease suppression was associated with the lower serum levels of autoantibodies, and the decreased frequencies of activated B cells and plasma cells. The expression levels of B cell activation/differentiation-related cytokines were suppressed in spleen and peripheral leukocytes of the 5C6-treated mice. Intriguingly, while untreated KO1 mice spontaneously developed marked monocytosis, the 5C6-treated mice showed the significantly down-regulated frequency of monocytes. The outcome of 5C6 treatment was complex, in which the 5C6-mediated disease-preventive effect is likely due on one hand to the decrease in the recruitment of inflammatory cells and osteoclast precursor monocytes from the periphery into the joints, and on the other hand to the suppression of B cell activation/maturation and of autoantibody production via the suppression of B cell stimulating cytokine production. The lower levels of these cytokines may be the secondary effect of the lower frequency of monocytes, since monocytes/macrophages are the major producers of these cytokines.
- 19 October 2016
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 27 (1) , 72-76
Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: The JUDE study
Objective: To clarify the clinical features of systemic lupus erythematosus (SLE) patients, factors associated with flares, and changes over time. Methods: Patients having SLE with a visiting history were entered into the Juntendo University Database of Erythematosus. We included 423 cases in the long-term follow-up analysis, and 383 cases were followed for 10 years after the initiation of any therapeutic intervention (comparative analysis: 1973–1982, 82 cases; 1983–1992, 141, and 1993–2002, 160). We assessed changes in the patients’ background characteristics, disease symptoms, flare rates, etc. Results: Among the 423 cases, the mean follow-up period was 25.9 years, and mean number of flares was 0.51. Of those, 31.9% had ≥1 flares. Thrombocytopenia at onset contributed to the flares. For disease symptoms at onset, a recent trend in increasing thrombocytopenia was observed. The combination rate of immunosuppressive agents for diseases other than lupus nephritis was slightly increased, and there was no improvement until the first flare or in the flare rate. Conclusions: Thrombocytopenia at onset is predictive factor for flares. Since SLE is a diverse disease with varying symptoms at recurrence, the treatment guidelines should be improved for thrombocytopenia from a long-term perspective.
- 19 October 2016
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 27 (1) , 72-76
Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: The JUDE study
Objective: To clarify the clinical features of systemic lupus erythematosus (SLE) patients, factors associated with flares, and changes over time. Methods: Patients having SLE with a visiting history were entered into the Juntendo University Database of Erythematosus. We included 423 cases in the long-term follow-up analysis, and 383 cases were followed for 10 years after the initiation of any therapeutic intervention (comparative analysis: 1973–1982, 82 cases; 1983–1992, 141, and 1993–2002, 160). We assessed changes in the patients’ background characteristics, disease symptoms, flare rates, etc. Results: Among the 423 cases, the mean follow-up period was 25.9 years, and mean number of flares was 0.51. Of those, 31.9% had ≥1 flares. Thrombocytopenia at onset contributed to the flares. For disease symptoms at onset, a recent trend in increasing thrombocytopenia was observed. The combination rate of immunosuppressive agents for diseases other than lupus nephritis was slightly increased, and there was no improvement until the first flare or in the flare rate. Conclusions: Thrombocytopenia at onset is predictive factor for flares. Since SLE is a diverse disease with varying symptoms at recurrence, the treatment guidelines should be improved for thrombocytopenia from a long-term perspective.
- 1 June 2015
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 74 (Suppl 2) , 572
FRI0402 Disease Flare Patterns and Predictors in a Long-Term Follow-Up of 423 Japanese SLE Patients from Monocentric Cohort Jude Study
Background Although the prognosis for systemic lupus erythematosus (SLE) has greatly improved, many patients experience the disease flare-up. Little is known about the disease flare-up patterns and predictors in a long-term follow up. Objectives The aim of this study was to clarify the outcomes and predictors for disease flare-up in a monocentric cohort of Japanese patients with SLE. Methods Among 2390 SLE patients registered in our JUDE (Juntendo University Database of Erythematosus) study, diagnosed between 1964 and 2004, 423 for whom long-term follow-up was possible between 1973 and 2012 were investigated. Disease activity patterns were defined using the SLE Disease Activity Index-2000 (SLEDAI-2K)1.Disease flare-up was defined according to the SELENA-SLEDAI flare composite2. SLE patients were included if they fulfilled the ARA3 or ACR4 criteria for SLE. Data on disease activity, severe flare-up and treatment were collected, and the initial clinical manifestations of disease flare-up were analyzed. The censoring period for analysis was May to October 2013. Results The mean follow-up duration was 25.9 years. During follow-up, 118 (27.9%) of the 423 patients experienced at least once flare-up after initial treatment with corticosteroid or corticosteroid plus immunosuppressant. More than half (58.5%) of the patients who suffered flare-up were accumulated within 5 years, irrespective of the initial therapy. Comparison of the age at onset among patients who suffered flare-up more than twice in 10 years after the initial therapy showed that teenage onset accounted for a greater proportion than patients who developed SLE in their thirties and beyond. The most common manifestation associated with flare-up was thrombocytopenia. Cluster analysis showed that renal disturbance was distinct from arthritis among manifestations of both onset and flare-up. Conclusions This long-term monocentric cohort follow-up study of 423 Japanese SLE patients revealed that 27.9% suffered flare-up after the initial therapy, irrespective of the initial treatment regimen. References Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 29(2):288-91. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, McCune WJ, Hearth-Holmes M, Dooley MA, Von Feldt J, Friedman A, Tan M, Davis J, Cronin M, Diamond B, Mackay M, Sigler L, Fillius M, Rupel A, Licciardi F, Buyon JP; OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 15;353(24):2550-8. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 25(11):1271-7. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 40(9):1725 Disclosure of Interest None declared
- 1 June 2015
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 74 (Suppl 2) , 572
FRI0402 Disease Flare Patterns and Predictors in a Long-Term Follow-Up of 423 Japanese SLE Patients from Monocentric Cohort Jude Study
Background Although the prognosis for systemic lupus erythematosus (SLE) has greatly improved, many patients experience the disease flare-up. Little is known about the disease flare-up patterns and predictors in a long-term follow up. Objectives The aim of this study was to clarify the outcomes and predictors for disease flare-up in a monocentric cohort of Japanese patients with SLE. Methods Among 2390 SLE patients registered in our JUDE (Juntendo University Database of Erythematosus) study, diagnosed between 1964 and 2004, 423 for whom long-term follow-up was possible between 1973 and 2012 were investigated. Disease activity patterns were defined using the SLE Disease Activity Index-2000 (SLEDAI-2K)1.Disease flare-up was defined according to the SELENA-SLEDAI flare composite2. SLE patients were included if they fulfilled the ARA3 or ACR4 criteria for SLE. Data on disease activity, severe flare-up and treatment were collected, and the initial clinical manifestations of disease flare-up were analyzed. The censoring period for analysis was May to October 2013. Results The mean follow-up duration was 25.9 years. During follow-up, 118 (27.9%) of the 423 patients experienced at least once flare-up after initial treatment with corticosteroid or corticosteroid plus immunosuppressant. More than half (58.5%) of the patients who suffered flare-up were accumulated within 5 years, irrespective of the initial therapy. Comparison of the age at onset among patients who suffered flare-up more than twice in 10 years after the initial therapy showed that teenage onset accounted for a greater proportion than patients who developed SLE in their thirties and beyond. The most common manifestation associated with flare-up was thrombocytopenia. Cluster analysis showed that renal disturbance was distinct from arthritis among manifestations of both onset and flare-up. Conclusions This long-term monocentric cohort follow-up study of 423 Japanese SLE patients revealed that 27.9% suffered flare-up after the initial therapy, irrespective of the initial treatment regimen. References Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 29(2):288-91. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, McCune WJ, Hearth-Holmes M, Dooley MA, Von Feldt J, Friedman A, Tan M, Davis J, Cronin M, Diamond B, Mackay M, Sigler L, Fillius M, Rupel A, Licciardi F, Buyon JP; OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 15;353(24):2550-8. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 25(11):1271-7. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 40(9):1725 Disclosure of Interest None declared
- Open Access
- 26 December 2012
- Published by Wiley in European Journal of Immunology
- Vol. 43 (3) , 770-778
Phenotype conversion from rheumatoid arthritis to systemic lupus erythematosus by introduction of Yaa mutation into FcγRIIB‐deficient C57BL/6 mice
We previously established an IgG Fc receptor IIB (FcγRIIB)‐deficient C57BL/6 (B6)‐congenic mouse strain (KO1), which spontaneously develops rheumatoid arthritis (RA), but not systemic lupus erythematosus (SLE). Here, we show that when Y chromosome‐linked autoimmune acceleration (Yaa) mutation was introduced in KO1 strain (KO1.Yaa), the majority of KO1.Yaa mice did not develop RA, but instead did develop SLE. This phenotype conversion did not depend on autoantibody specificity, since KO1.Yaa mice, compared with KO1, showed a marked increase in serum levels of both lupus‐related and RA‐related autoantibodies. The increase in frequencies of CD69+ activated B cells and T cells, and the spontaneous splenic GC formation with T follicular helper cell generation were manifest early in life of KO1.Yaa, but not KO1 and B6.Yaa, mice. Activated CD4+ T cells from KO1.Yaa mice showed upregulated production of IL‐21 and IL‐10, compared with the finding in KO1 mice, indicating the possibility that this aberrant cytokine milieu relates to the disease phenotype conversion. Thus, our model is useful to clarify the shared and the disease‐specific mechanisms underlying the clinically distinct systemic autoimmune diseases RA and SLE.
- 26 December 2012
- Published by Wiley in European Journal of Immunology
- Vol. 43 (3) , 770-778
Open AccessPhenotype conversion from rheumatoid arthritis to systemic lupus erythematosus by introduction of Yaa mutation into FcγRIIB‐deficient C57BL/6 mice
We previously established an IgG Fc receptor IIB (FcγRIIB)‐deficient C57BL/6 (B6)‐congenic mouse strain (KO1), which spontaneously develops rheumatoid arthritis (RA), but not systemic lupus erythematosus (SLE). Here, we show that when Y chromosome‐linked autoimmune acceleration (Yaa) mutation was introduced in KO1 strain (KO1.Yaa), the majority of KO1.Yaa mice did not develop RA, but instead did develop SLE. This phenotype conversion did not depend on autoantibody specificity, since KO1.Yaa mice, compared with KO1, showed a marked increase in serum levels of both lupus‐related and RA‐related autoantibodies. The increase in frequencies of CD69+ activated B cells and T cells, and the spontaneous splenic GC formation with T follicular helper cell generation were manifest early in life of KO1.Yaa, but not KO1 and B6.Yaa, mice. Activated CD4+ T cells from KO1.Yaa mice showed upregulated production of IL‐21 and IL‐10, compared with the finding in KO1 mice, indicating the possibility that this aberrant cytokine milieu relates to the disease phenotype conversion. Thus, our model is useful to clarify the shared and the disease‐specific mechanisms underlying the clinically distinct systemic autoimmune diseases RA and SLE.
- 11 February 2010
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 20 (3) , 295
Erratum to: Improvement of rapidly progressive lupus nephritis associated MPO-ANCA with tacrolimus
- 11 February 2010
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 20 (3) , 295
Erratum to: Improvement of rapidly progressive lupus nephritis associated MPO-ANCA with tacrolimus
- 1 January 2010
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 99 (6) , 1324-1326
A Case of Disseminated Nocardiosis Complicated with Adult Onset Still's Disease.
50歳,女性,2008年5月成人Still病と診断された.同年10月prednisolone(PSL):0.65mg/kg内服中,発熱,背部の皮下膿瘍を認め,肺,脳実質内に空洞を伴い多発する浸潤影が出現,また血液と皮下膿瘍からNocardia farcinicaが同定され播種性ノカルジア症と診断した.sulfamethoxazol-trimethoprim(ST合剤)による治療を開始したが副作用のため中止,imipenem/cilastatin(IPM/CS),amikacin(AMK)を6週間投与したところ病変はほぼ消失した.その後moxifloxacin(MFLX)の内服に切り替え,病変の再燃はない.
- 1 January 2010
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 99 (6) , 1324-1326
A Case of Disseminated Nocardiosis Complicated with Adult Onset Still's Disease.
50歳,女性,2008年5月成人Still病と診断された.同年10月prednisolone(PSL):0.65mg/kg内服中,発熱,背部の皮下膿瘍を認め,肺,脳実質内に空洞を伴い多発する浸潤影が出現,また血液と皮下膿瘍からNocardia farcinicaが同定され播種性ノカルジア症と診断した.sulfamethoxazol-trimethoprim(ST合剤)による治療を開始したが副作用のため中止,imipenem/cilastatin(IPM/CS),amikacin(AMK)を6週間投与したところ病変はほぼ消失した.その後moxifloxacin(MFLX)の内服に切り替え,病変の再燃はない.